BRUKER (BRKR) Company Report

Bruker reported a mixed Q3 2025, with order bookings exceeding revenue (book-to-bill ratio over one), but revenue was down 4.7% and EPS fell 25% year-over-year to $0.45. Profitability was impacted by U.S. academic/government weakness, China stimulus delays, tariffs, and foreign exchange.
The company sees strong order performance in biopharma and expects China revenue to grow in 2026 after a decline in 2025, driven by biopharma and industrial segments. New product launches, TIMS Omni and TIMS Metabo (introduced June 2025), have received early orders, with revenue recognition anticipated in Q2 or Q3 2026.
The ELITechGroup acquisition (April 2024) is performing well, contributing approximately $190 million in 2025 revenues and expanding Bruker's molecular diagnostics business to roughly $500 million with a focus on sustainable recurring revenue.
Bruker's capital deployment strategy prioritizes R&D and CapEx, with a focus on debt reduction to achieve a leverage ratio closer to 2.7 from the current ~3. Large acquisition activity is not planned in the short term.

3 days ago

Transcript

Bruker Discusses Q3 2025 Performance and Future Strategy

BRKR

Earnings

Guidance Update

M&A

Bruker reported a mixed third quarter 2025, with a book-to-bill ratio of over one and revenue over $860 million, but revenue was down about 4.7% and EPS at $0.45 was down about 25% year-over-year. Profitability was challenged by U.S. academic/government weakness, China stimulus funding delays, tariffs, and foreign exchange.
Order performance showed significant strength in academic and government research outside the U.S. and in biopharma, with biopharma momentum continuing into Q4. The company expects muted performance in the U.S. academic and government segment for 2026, looking to Europe, Japan, and China for growth.
China, representing 13%-15% of total revenue, saw declining revenue over the past 1.5 years, expected to be down in the low single digits for 2025, but showed solid order performance in Q3 2025 and is anticipated to grow in 2026, particularly in biopharma and industrial segments.
New mass spectrometry products, timsOmni and timsMetabo, launched in June 2025, have already received orders in Q3 2025, with revenue recognition expected in Q2 or Q3 2026, and are projected to significantly contribute to revenue in 2026 and beyond.
The April 2024 acquisition of ELITechGroup is performing well, expected to contribute $190 million in revenues for 2025, expanding Bruker's molecular diagnostics business to roughly $500 million and providing a valuable recurring revenue stream. Bruker is currently on a "deal diet" for large M&A, prioritizing R&D, CapEx, and debt reduction to a leverage ratio of 2.7 from the current 3.

3 days ago

Transcript

Bruker Discusses Q3 2025 Results, Market Dynamics, and Strategic Focus at Nasdaq Investor Conference

BRKR

Guidance Update

Product Launch

M&A

Bruker reported a mixed third quarter of 2025, with a book-to-bill ratio of over one and revenue of over $860 million, but revenue was down 4.7% and EPS was $0.45, a 25% year-over-year decrease, primarily due to U.S. ACAGOV weakness, China stimulus delays, tariffs, and foreign exchange impacts.
The company observed strong order performance in academic and government research outside the U.S. and in biopharma, with biopharma exposure between 15%-20% of total revenue and positive traction expected in Japan, China, and Europe. China, representing 13%-15% of total revenue, is expected to see year-over-year growth in 2026 from a weak 2025 comparative base.
Bruker launched new mass spectrometry products, TIMS Omni and TIMS Metabo, in June 2025, which have already received orders and are expected to contribute significantly to revenue from Q2 or Q3 2026.
Following the April 2024 acquisition of ELITechGroup, projected to generate $190 million in revenues for 2025, Bruker aims to grow its molecular diagnostics business to approximately $500 million through sustainable recurring revenue. The company is currently on a "deal diet" for large M&A, prioritizing R&D, CapEx, and debt reduction to achieve a leverage ratio of 2.7 from the current 3.

3 days ago

Transcript

Bruker Corporation Discusses Q3 Performance, Q4 Outlook, and 2026 Financial Targets

BRKR

Guidance Update

Demand Weakening

M&A

Bruker's Q3 revenue came in better than expected, driven by strength in the Life Science Mass Spectrometry and AXS businesses, as well as double-digit revenue performance in the defense area, particularly in European markets. The operating margin of 12.3% also exceeded street estimates, primarily due to mix improvement in the LSMS business.
The Q4 2025 revenue guide was lowered due to approximately $40 million in semiconductor business orders pushing out to the first half of 2026, alongside government shutdown elements.
The company expects $120 million in annualized cost savings, representing almost 10% of total OPEX, with this run rate continuing through 2026. This is projected to lead to 300 basis points of operating margin improvement in 2026, even with flat growth.
Bruker is targeting double-digit EPS growth in 2026, specifically in the mid-teens, which includes the impact of mandatory convertible preferreds. This growth is supported by anticipated flat to low single-digit organic revenue growth in 2026, driven by strong biopharma and international academic/government order demand, and pricing actions of 3-6%.

Nov 17, 2025, 9:00 PM

Transcript

Bruker Corporation Discusses Q3 Performance, Q4 Outlook, and 2026 Financial Targets

BRKR

Guidance Update

Revenue Acceleration/Inflection

Convertible Preferred Issuance

Bruker Corporation reported better-than-expected Q3 2025 revenue and an operating margin of 12.3%, surpassing street estimates of approximately 9%.
The company expects to implement $30 million+ in cost actions in Q4 2025 and projects $120 million in annualized cost savings to run through 2026, representing almost 10% of total OPEX.
For 2026, Bruker anticipates flat to low single-digit organic revenue growth and is confident in achieving 300 basis points of operating margin improvement and double-digit EPS growth (mid-teens), even after accounting for Mandatory Convertible Preferred impact.
A $40 million push-out of semiconductor-related revenue from Q4 2025 into H1 2026 is expected, alongside pricing actions targeting 3%-6% adjustments to enhance revenue and gross margin.

Nov 17, 2025, 9:00 PM

Transcript

Bruker Discusses Q3 2025 Performance and 2026 Outlook

BRKR

Guidance Update

Demand Weakening

Revenue Acceleration/Inflection

Bruker's Q3 2025 revenue exceeded expectations, with strong performance in Life Science Mass Spectrometry, AXS business, and defense, while operating margin reached 12.3%, surpassing street estimates.
The company's Q4 2025 guidance was lowered primarily due to a $40 million push-out of semiconductor orders into the first half of 2026 and government shutdown elements.
For 2026, Bruker projects flat to low single-digit organic revenue growth and is confident in achieving 300 basis points of operating margin improvement, driven by $120 million in cost savings and 3-6% pricing actions.
The company is targeting mid-teens double-digit EPS growth in 2026, even after accounting for mandatory convertible preferred impact.

Nov 17, 2025, 9:00 PM

Transcript

Bruker Reports Q3 2025 Results and Updates Full-Year Guidance

BRKR

Earnings

Guidance Update

Demand Weakening

Bruker's Q3 2025 reported revenues decreased 0.5% to $860.5 million, reflecting an organic revenue decrease of 4.5%. Non-GAAP diluted EPS for the quarter was $0.45, a 25% decrease from Q3 2024, but a sequential improvement from Q2 2025.
The company's non-GAAP operating margin for Q3 2025 was 12.3%, a 260 basis point decrease year-over-year, but represented a meaningful sequential improvement over the 9.0% reported in Q2 2025.
For the full year 2025, Bruker updated its revenue forecast to a range of $3.41 billion-$3.44 billion, which implies an organic revenue decline of 4%-5%. The updated non-GAAP EPS guidance for the full year is $1.85-$1.90.
Order bookings in the Scientific Instruments (BSI) segment were up organically in the mid-single digit percentage year-over-year in Q3 2025, resulting in a book-to-bill ratio above 1.0. The company's backlog increased to about seven months through Q3 2025, up from six and a half months at the end of Q2.

Nov 3, 2025, 1:30 PM

Transcript

Bruker Corporation Reports Q3 2025 Results and Updates FY 2025 Outlook

BRKR

Earnings

Guidance Update

Demand Weakening

Bruker Corporation reported a 0.5% decrease in Q3 2025 revenue to $860.5 million, with non-GAAP EPS declining 25% year-over-year to $0.45.
Year-to-date Q3 2025 revenue increased 3.0% to $2,459.3 million, but non-GAAP EPS decreased 25.5% to $1.23, including a $0.09 FX headwind.
The company experienced research instrument demand headwinds, resulting in an organic revenue decline of 4.5% in Q3 2025 and 3.1% year-to-date.
Bruker updated its FY 2025 financial outlook, projecting reported revenue growth of +1% to +2% and non-GAAP EPS between $1.85 and $1.90, which represents a 21% to 23% decline year-over-year.
Year-to-date Q3 2025 free cash flow was -$163.9 million, impacted by reduced net income, timing of payments, and FX headwinds; cash and debt balances reflect $672 million in net proceeds from mandatory convertible preferred in September 2025 used for debt paydown.

Nov 3, 2025, 1:30 PM

Presentation

Bruker Reports Q3 2025 GAAP Loss, Trims Full-Year Guidance

BRKR

Earnings

Guidance Update

Demand Weakening

Bruker reported Q3 2025 revenue of $860.5 million, which was essentially flat year-over-year, and a GAAP diluted loss of $(0.41), primarily due to non-cash impairment and restructuring charges. Non-GAAP EPS for the quarter was $0.45.
The company trimmed its FY2025 revenue guidance to $3.41–3.44 billion and lowered its full-year adjusted EPS guidance to $1.85–1.90.
Key financial metrics showed weakness, with organic revenue declining approximately 4.5% year-over-year, operating margin compressing to -6%, and free cash flow being negative $54.1 million, reflecting near-term demand softness.
Management highlighted mid-single-digit organic bookings growth and improving demand in academic/government, biopharma, and applied markets, and is targeting $100–120 million in cost savings for 2026 to drive future operating margin expansion and EPS recovery.

Nov 3, 2025, 12:09 PM

Morningstar

Bruker Reports Q3 2025 Financial Results and Updates FY2025 Guidance

BRKR

Earnings

Guidance Update

Demand Weakening

Bruker reported Q3 2025 revenues of $860.5 million, a 0.5% decrease year-over-year, with an organic decline of 4.5%. GAAP diluted loss per share was $(0.41), while non-GAAP diluted earnings per share stood at $0.45.
The company updated its FY2025 revenue guidance to $3.41 to $3.44 billion, projecting 1-2% reported growth year-over-year and an organic decline of 4-5%.
FY2025 non-GAAP EPS guidance was lowered to $1.85 to $1.90 due to previous market weakness and EPS dilution from a higher share count.
Despite revenue declines, Bruker experienced mid-single digit percentage organic bookings growth year-over-year in Q3 2025, with the Scientific Instruments segment achieving a book-to-bill ratio greater than 1.0.

Nov 3, 2025, 12:00 PM

8-K

Earnings Transcripts

Quarterly earnings call transcripts for BRUKER.

Q3 2025

Nov 3, 2025

→

Q2 2025

Aug 4, 2025

→

Q1 2025

May 7, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Frank H. Laukien say about margins?What are BRUKER's strategic priorities?How is BRUKER positioned vs competitors?How did BRUKER do last quarter?

BRUKER (BRKR)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Frank H. Laukien

Burkhard A. Prause

Falko Busse

Gerald N. Herman

Juergen W. Srega

Mark R. Munch

Board Members

Adelene Q. Perkins

Bonnie H. Anderson

Cynthia M. Friend

Hermann F. Requardt

John A. Ornell

Laura A. Francis

Richard A. Packer

Robert J. Rosenthal

William A. Linton

Analyst Coverage

Luke Sergott

Patrick Donnelly

Puneet Souda

Tycho Peterson

Michael Ryskin

Rachel Vatnsdal Olson

Daniel Brennan

Joshua Waldman

S. Brandon Couillard

Subhalaxmi Nambi

Brandon Couillard

Douglas Schenkel

Doug Schenkel

Marta Nazarovets Zaremba

Subbu Nambi

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent